What does an IDH mutation mean for my glioma?

An IDH mutation is a change in the IDH1 or IDH2 gene found in the tumour cells. In glioma, it is the single most powerful prognostic marker. At the same grade, an IDH-mutant glioma tends to grow more slowly and is linked with significantly longer survival than an IDH wild-type tumour. Under the WHO 2021 classification, IDH status now helps define the tumour type itself — not just its grade. It does not promise a cure, but it usually means a more favourable outlook and a different treatment plan. The result comes from the biopsy or surgery tissue, so a confirmed IDH status is essential before any long-term plan is finalised.

What is the difference between IDH-mutant and IDH wild-type glioma?

The two behave very differently. IDH-mutant gliomas are more common in younger adults, grow more slowly, and as a group carry a better prognosis. IDH wild-type glioma — in an adult with the right features — is treated as a more aggressive tumour, and most adult glioblastomas are IDH wild-type. Because the biology differs, the treatment intensity, the radiation and systemic-therapy decisions, and the follow-up schedule all differ. This is why two people with the "same" grade of glioma can be given very different plans. Knowing the IDH status removes the guesswork. CION arranges IDH testing as standard on every malignant glioma sample.

What is an IDH-mutant astrocytoma?

An IDH-mutant astrocytoma is a glioma that arises from astrocyte support cells and carries an IDH mutation but does not have the 1p/19q co-deletion (that combination instead defines an oligodendroglioma). Under WHO 2021, IDH-mutant astrocytomas are graded 2, 3, or 4. They generally grow more slowly than IDH wild-type tumours and are more common in adults aged roughly 30 to 50. Treatment is tailored to the grade, the extent of safe surgical removal, and other molecular features such as CDKN2A/B status. Because outcomes can be measured in years, accurate molecular typing at diagnosis matters a great deal for planning.

How is IDH status tested, and who arranges it?

IDH status is checked on the actual tumour tissue obtained from surgery or a stereotactic biopsy. Pathologists commonly use immunohistochemistry to spot the most frequent mutation (IDH1 R132H), and add gene sequencing when that stain is negative, to catch rarer IDH1 and IDH2 changes. It cannot be diagnosed from an MRI scan alone — imaging can only suggest the likelihood. At CION, IDH and other markers such as MGMT and 1p/19q are arranged together as part of the standard molecular work-up on every malignant glioma, so the full picture is ready when the tumour board plans your care.

Are there treatments that specifically target the IDH mutation?

Yes — for some patients. A class of medicines known as IDH inhibitors is now an established option for selected IDH-mutant Grade 2 gliomas, used after surgery to delay the need for radiation or chemotherapy in suitable cases. Whether an IDH inhibitor is appropriate depends on the grade, the residual tumour, symptoms, and the overall plan agreed by the tumour board. The mainstays of care still include safe surgical removal (coordinated with our accredited neurosurgical partners), radiation therapy, and systemic therapy where indicated. CION discusses targeted options as part of an individualised, guideline-based plan rather than a one-size-fits-all approach.

Does an IDH mutation mean my glioma is curable?

An IDH mutation is encouraging news, but it is not a guarantee of cure. IDH-mutant gliomas usually grow more slowly and are associated with longer survival than IDH wild-type tumours — outcomes are often measured in many years, and some lower-grade tumours can be controlled for a long time. However, gliomas can still recur or change over time, so long-term monitoring with periodic MRI is part of the plan. The honest message is one of cautious optimism: a more favourable biology, a more measured treatment pace, and a focus on protecting your function and quality of life. We frame survival as published ranges, never as a promise.

Why does the WHO 2021 change matter for me?

Before 2021, gliomas were classified mainly on how the cells looked under the microscope. The WHO 2021 classification made molecular markers — especially IDH and 1p/19q — central to the diagnosis itself. This means the name of your tumour, its grade, and the recommended treatment can all depend on the molecular result, not just the appearance of the cells. For you, it means a biopsy report without IDH status is incomplete for planning. If you were diagnosed before these tests were arranged, a second opinion that re-tests the stored tissue can sometimes refine the diagnosis and the plan. Read more on our molecular testing page.